Bristol-Myers Squibb Company
HealthcareNYSE:BMY · New York Stock Exchange
+$0.23 today
Vol 3.62M · Avg 11.55M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $9.6B |
| Short-term Investments | $912.0M |
| Receivables | $9.4B |
| Inventory | $2.8B |
| Other Current | $4.6B |
| Total Current Assets | $27.2B |
| PP&E (Net) | $7.7B |
| Goodwill | $21.7B |
| Intangible Assets | $18.2B |
| Tax Assets | $5.2B |
| Other Non-current | $6.5B |
| Total Non-current Assets | $59.3B |
| Total Assets | $86.5B |
Analysis
Selected assets total $86.5B for Latest. The largest visible component is Goodwill at $21.7B, about 25.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.2B -1.3% | $10.3B -9.8% | $11.5B +25.7% | $9.1B -34.7% | $14.0B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $464.0M -9.6% | $513.0M -37.1% | $816.0M +527.7% | $130.0M -96.0% | $3.2B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $14.5B +0.7% | $14.4B -5.5% | $15.3B +9.5% | $13.9B +11.4% | $12.5B | $533.8M | $399.4M | -$1.7B |
| Inventory | $2.7B +5.2% | $2.6B -3.9% | $2.7B +13.8% | $2.3B +11.6% | $2.1B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.5B -22.6% | $1.9B +24.0% | $1.6B -10.3% | $1.7B +22.0% | $1.4B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $29.4B -1.3% | $29.8B -6.3% | $31.8B +16.5% | $27.3B -18.0% | $33.3B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $9.1B +9.2% | $8.4B +4.0% | $8.0B +7.5% | $7.5B +7.3% | $7.0B | $1.2B | $1.5B | $687.8M |
| Goodwill | $21.8B +0.2% | $21.7B +2.6% | $21.2B +0.1% | $21.1B +3.2% | $20.5B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $19.1B -19.2% | $23.6B -14.0% | $27.5B -24.4% | $36.4B -15.0% | $42.8B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $2.5B -0.0% | $2.5B +0.4% | $2.5B +14.3% | $2.2B -19.4% | $2.7B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $5.4B +27.0% | $4.2B +53.0% | $2.8B +106.0% | $1.3B -6.6% | $1.4B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $2.8B +18.0% | $2.4B +64.6% | $1.4B +38.1% | $1.0B -37.3% | $1.7B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $60.6B -3.5% | $62.8B -0.9% | $63.4B -8.9% | $69.5B -8.6% | $76.1B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $90.0B -2.8% | $92.6B -2.7% | $95.2B -1.7% | $96.8B -11.4% | $109.3B | $13.3B | $11.9B | $10.6B |
| Account Payables | $3.6B -0.7% | $3.6B +10.5% | $3.3B +7.2% | $3.0B +3.1% | $2.9B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $2.3B +10.5% | $2.0B -34.4% | $3.1B -26.9% | $4.3B -13.8% | $4.9B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $979.0M -35.3% | $1.5B +10.4% | $1.4B +45.5% | $942.0M +24.9% | $754.0M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $14.6B +0.2% | $14.6B +14.2% | $12.8B +6.7% | $12.0B +4.4% | $11.5B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $23.4B -1.5% | $23.8B +6.8% | $22.3B +1.7% | $21.9B +0.1% | $21.9B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $42.9B -10.0% | $47.6B +29.9% | $36.7B +4.6% | $35.1B -11.5% | $39.6B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $222.0M -39.8% | $369.0M +9.2% | $338.0M -84.4% | $2.2B -51.9% | $4.5B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $169.0M -26.5% | $230.0M -23.3% | $300.0M +6.0% | $283.0M -13.2% | $326.0M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $3.0B +6.2% | $2.9B -37.5% | $4.6B -9.0% | $5.0B -17.7% | $6.1B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $48.1B -8.2% | $52.4B +20.8% | $43.4B -0.9% | $43.8B -14.8% | $51.4B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $71.5B -6.1% | $76.2B +16.1% | $65.7B -0.0% | $65.7B -10.4% | $73.3B | $14.7B | $3.7B | $9.6B |
| Common Stock | $292.0M +0.0% | $292.0M +0.0% | $292.0M +0.0% | $292.0M +0.0% | $292.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $16.9B +13.3% | $14.9B -48.2% | $28.8B +12.8% | $25.5B +7.1% | $23.8B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$1.5B -23.0% | -$1.2B +19.9% | -$1.5B -20.7% | -$1.3B -1.0% | -$1.3B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $33.0M -37.7% | $53.0M -3.6% | $55.0M -3.5% | $57.0M -5.0% | $60.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $18.5B +12.9% | $16.4B -44.4% | $29.5B -5.2% | $31.1B -13.6% | $36.0B | $9.1B | $7.7B | $3.3B |
| Total Debt | $47.1B -7.9% | $51.2B +23.5% | $41.5B +1.8% | $40.7B -10.7% | $45.6B | $724.2M | $410.6M | $399.4M |
| Net Debt | $36.9B -9.6% | $40.9B +36.2% | $30.0B -5.0% | $31.6B -0.1% | $31.6B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Pfizer Inc.
NYSE:PFE
$149.18B
CVS Health Corporation
NYSE:CVS
$129.95B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.63B
GSK plc
NYSE:GSK
$106.57B
Sanofi
NASDAQ:SNY
$106.45B
McKesson Corporation
NYSE:MCK
$94.81B
Elevance Health Inc.
NYSE:ELV
$87.31B
HCA Healthcare, Inc.
NYSE:HCA
$85.73B
Cigna Corporation
NYSE:CI
$78.87B
Zoetis Inc.
NYSE:ZTS
$33.66B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does BMY have?
Bristol-Myers Squibb Company (BMY) reported $10.21B in cash and equivalents in fiscal 2025.
How much debt does BMY carry?
Bristol-Myers Squibb Company (BMY) reported $47.14B of total debt, with net debt of $36.93B.
Explore More
Continue the stock analysis
Jump to another research area for this company.